Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: Economic analysis of a phase 4 randomized, controlled trial

Journal of Urology

Volumn 191, Issue 6, 2014, Pages 1721-1727

  Kauf, Teresa L ^a   Svatek, Robert S ^b   Amiel, Gilad ^c   Beard, Timothy L ^e   Chang, Sam S ^f   Fergany, Amr ^g   Karnes, R Jeffrey ^h   Koch, Michael ^j   O'Hara, Jerome ^g   Lee, Cheryl T ^k   Sexton, Wade J ^l   Slaton, Joel W ^m   Steinberg, Gary D ⁿ   Wilson, Shandra S ^o   Techner, Lee ^a   Martin, Carolyn ⁱ   Moreno, Jessica ^a   Kamat, Ashish M ^d  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e Bend Memorial Clinic   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h MAYO CLINIC   (United States)

ⁱ OPTUM   (United States)

^j INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

^l H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^m UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

ⁿ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^o UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

cost benefit analysis; gastrointestinal tract; ileus; postoperative complications; urinary bladder

Indexed keywords

ALVIMOPAN; MU OPIATE RECEPTOR ANTAGONIST; PLACEBO; GASTROINTESTINAL AGENT; MU OPIATE RECEPTOR; PIPERIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BOOTSTRAPPING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CYSTECTOMY; DOUBLE BLIND PROCEDURE; ECONOMIC EVALUATION; ELECTROCARDIOGRAM; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITAL READMISSION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTICENTER STUDY; NASOGASTRIC TUBE; PHASE 4 CLINICAL TRIAL; POSTOPERATIVE ILEUS; PRIORITY JOURNAL; REIMBURSEMENT; SENSITIVITY ANALYSIS; TOTAL PARENTERAL NUTRITION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COST; ECONOMICS; FOLLOW UP; HOSPITAL COST; ILEUS; INCIDENCE; ORAL DRUG ADMINISTRATION; PATIENT ATTITUDE; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES;

ADMINISTRATION, ORAL; COSTS AND COST ANALYSIS; CYSTECTOMY; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HOSPITAL COSTS; HUMANS; ILEUS; INCIDENCE; PATIENT ACCEPTANCE OF HEALTH CARE; PIPERIDINES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RECEPTORS, OPIOID, MU; UNITED STATES;

EID: 84900445904     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.12.015     Document Type: Article

References (30)

1. S.S. Chang, R.G. Baumgartner, and N. Wells et al. Causes of increased hospital stay after radical cystectomy in a clinical pathway setting J Urol 167 2002 208
2. S.M. Donat, A. Shabsigh, and C. Savage et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience Eur Urol 55 2009 177
3. M.H. Hayn, N.J. Hellenthal, and A. Hussain et al. Defining morbidity of robot-assisted radical cystectomy using a standardized reporting methodology Eur Urol 59 2011 213
4. B.K. Hollenbeck, D.C. Miller, and D. Taub et al. Identifying risk factors for potentially avoidable complications following radical cystectomy J Urol 174 2005 1231
5. N. Lawrentschuk, R. Colombo, and O.W. Hakenberg et al. Prevention and management of complications following radical cystectomy for bladder cancer Eur Urol 57 2010 983
6. W.T. Lowrance, J.A. Rumohr, and S.S. Chang et al. Contemporary open radical cystectomy: analysis of perioperative outcomes J Urol 179 2008 1313
7. W.M. Hilton, Y. Lotan, and D.J. Parekh et al. Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis BJU Int 111 2012 1054
8. C.P. Delaney, C. Craver, and M.M. Gibbons et al. Evaluation of clinical outcomes with alvimopan in clinical practice: a national matched-cohort study in patients undergoing bowel resection Ann Surg 255 2012 731
9. M.G. Doorly, and A.J. Senagore Pathogenesis and clinical and economic consequences of postoperative ileus Surg Clin North Am 92 2012 259
10. A.J. Senagore Pathogenesis and clinical and economic consequences of postoperative ileus Am J Health Syst Pharm 64 2007 S3
11. T.J. Bell, S.A. Poston, and M.D. Kraft et al. Economic analysis of alvimopan in North American phase III efficacy trials Am J Health Syst Pharm 66 2009 1362
12. M.W. Buchler, C.M. Seiler, and J.R.T. Monson et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study Aliment Pharmacol Ther 28 2008 312
13. C.P. Delaney, J.L. Weese, and N.H. Hyman et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery Dis Colon Rectum 48 2005 1114
14. K. Ludwig, W.E. Enker, and C.P. Delaney et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway Arch Surg 143 2008 1098
15. E.R. Viscusi, S. Goldstein, and T. Witkowski et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study Surg Endosc 20 2006 64
16. R. Whelpley, M. Pierce, and R. Collins et al. An evaluation of alvimopan use as part of perioperative management of patients undergoing laparoscopic small and large bowel resections Hosp Pharm 46 2011 26
17. B.G. Wolff, F. Michelassi, and T.M. Gerkin et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus Ann Surg 240 2004 728
18. A.M. Kamat, S.S. Chang, and C. Lee et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, accelerates gastrointestinal recovery and decreases length of hospital stay after radical cystectomy J Urol 189 suppl. 2013 e767 abstract 1870
19. Lee CT, Chang SS, Kamat AM, et al. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol 2014. Epub ahead of print.
20. Optum: EncoderPro.com. Available at http://www.encoderpro.com. Accessed November 25, 2013.
21. Centers for Medicare & Medicaid Services: FY 2012 Final Rule, Correction Notice and 1442-N (508 Wage Index) Tables. Available at http://cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/ FY-2012-IPPS-Final-Rule-Home-Page-Items/CMS1250520.html. Accessed September 19, 2013.
22. Centers for Medicare & Medicaid Services: Clinical Laboratory Fee Schedule. Available at http://www.cms.gov/Medicare/Medicare-Fee-for-Service- Payment/ClinicalLabFeeSched/clinlab.html. Accessed September 19, 2013.
23. Physicians' Fee and Coding Guide 2012 MagMutual Atlanta
24. R. Lee, C.K. Ng, and S.F. Shariat et al. The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy BJU Int 108 2011 1886
25. J.A. Barber, and S.G. Thompson Analysis of cost data in randomized trials: an application of the non-parametric bootstrap Stat Med 19 2000 3219
26. A.A. Vora, A. Harbin, and R. Rayson et al. Alvimopan provides rapid gastrointestinal recovery without nasogastric tube decompression after radical cystectomy and urinary diversion Can J Urol 19 2012 6293
27. R.S. Pruthi, J. Chun, and M. Richman Reducing time to oral diet and hospital discharge in patients undergoing radical cystectomy using a perioperative care plan Urology 62 2003 661
28. S. Poston, M.S. Broder, and M.M. Gibbons et al. Impact of alvimopan (entereg) on hospital costs after bowel resection: results from a large inpatient database P T 36 2011 209
29. D.R. Touchette, Y. Yang, and F. Tiryaki et al. Economic analysis of alvimopan for prevention and management of postoperative ileus Pharmacotherapy 32 2012 120
30. C.D. Scales Jr., P.J. Jones, and E.L. Eisenstein et al. Local cost structures and the economics of robot assisted radical prostatectomy J Urol 174 2005 2323